Structurally complex compounds exhibiting diverse anticancer activity profiles

Natural products have historically provided a major source of drugs and therapeutic agents; for example, about 50% of anticancer drugs and 60% of antibacterial drugs are natural products or semisynthetic derivatives thereof. Skeletal diversity and high stereochemical content are well-known attributes that endow natural products with the ability to engage a variety of biological molecules with high affinity and specificity, leading to biological and pharmacological activity. Notably, while a number of synthetic strategies have been explored for the generation of natural product-like molecules, none of them utilizes an enzyme-catalyzed C–H oxidation or epoxidation step as a means for generating structurally diverse new molecules from a parent scaffold.

Technology Overview
This technology provides for novel natural product-like molecules obtained through the chemoenzymatic re-elaboration and modification of parthenolide, a plant-derived natural product that has found use for the treatment of pain, migraine, and rheumatoid arthritis, as well as in antitumor, antiviral, and antileishmanial applications. In particular, enzymatic functionalization of parthenolide is combined with a series of molecular rearrangement and editing reactions resulting in a library of new and complex natural product-like molecules. These molecules exhibit potent anticancer activity as well as a diverse anticancer activity profile, including compounds with broad‑spectrum activity against multiple types of cancers as well as compounds with cancer-type specificity

These compounds exhibit high structural and stereochemical complexity akin to that found in natural products and encompass a diverse set of new molecular scaffolds possessing biological activity. In particular, they possess potent and diverse anticancer activity as well as the potential for antimicrobial, antibiotic, antifungal, and anti-inflammatory activity. Owing to the optional presence of an electrophilic ‘warhead’ in their structure, these compounds are also well suited for covalent engagement of their biomolecular target, including their use as molecular glues for targeted protein degradation.

Cancer treatment.

The university seek to license the technology exclusively.


  • Licensing

IP Status

  • Patent application submitted

Suggested Companies

  • Celgene Corp
  • Johnson & Johnson
  • Bristol Myers Squibb
  • Novartis
  • AXIM Biotechnologies
  • NatureWell
  • Aadi Bioscience
  • PharmaCyte Biotech
  • Chordia Therapeutics
  • Linnaeus Therapeutics
  • Cybrexa Therapeutics
  • Eisai
  • SAB Biotherapeutics
  • Proteome Sciences


Contact Information

TTO Home Page:

Name: Curtis Broadbent

Title: Licensing Manager

Department: UR Ventures


Phone: 585.273.3250